We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Celldex

News List

Celldex Therapeutics Appoints CMO contractpharma
June 25, 2019
Young brings 30 years of experience leading clinical and cross-functional R&D teams.
Celldex plans life after glembatumumab, cutting 2 more drugs from pipeline fiercebiotech
May 16, 2018
Still reeling from the failure of its lead breast cancer candidate glembatumumab vedotin last month, Celldex has culled another two pipeline projects and now says it will focus its R&D efforts mainly on two cancer antibodies.
Stock Dives as Celldex Cuts 20% of Staff After Phase II Breast Cancer Failure biospace
April 26, 2018
On April 16, Celldex Therapeutics reported that its Phase IIb trial of glembatumumab vedotin (glemba) failed in a trial of metastatic triple-negative breast cancer